Skip to main content
Top
Published in: Annals of Hematology 10/2005

01-10-2005 | Short Communication

Mutations of the HFE gene among Turkish hereditary hemochromatosis patients

Authors: Halis Simsek, Yasemin H. Balaban, Engin Yilmaz, Hale Sumer, Yahya Buyukasik, Cem Cengiz, Osman Ozcebe, Gulsen Hascelik, Gonca Tatar

Published in: Annals of Hematology | Issue 10/2005

Login to get access

Abstract

Since the discovery of the HFE gene, C282Y and H63D mutations have been reported as significantly correlated with clinically manifested hereditary hemochromatosis (HH). As the other genes involved in iron metabolism have been described, non-HFE cases of HH have been identified. Since in the general Turkish population, the C282Y mutation is not found and the H63D mutation is of high frequency, we aimed to determine mutations in the HFE genes in our patients with HH. The HFE gene of the five patients with HH were sequenced. C282Y mutation was absent, and all HH patients were heterozygote for H63D mutation. No other mutation was found in HFE gene by sequencing. Although the higher allele frequency of the H63D mutation in Turkish HH patients than in the general population implies a role of the H63D mutation in iron overload, there is a strong possibility that Turkish HH patients have non-HFE hemochromatosis.
Literature
2.
go back to reference Harrison SA, Bacon BR (2005) Relation of hemochromatosis with hepatocellular carcinoma: epidemiology, natural history, pathophysiology, screening, treatment, and prevention. Med Clin North Am 89:391–409CrossRefPubMed Harrison SA, Bacon BR (2005) Relation of hemochromatosis with hepatocellular carcinoma: epidemiology, natural history, pathophysiology, screening, treatment, and prevention. Med Clin North Am 89:391–409CrossRefPubMed
3.
go back to reference Felitti VJ, Beutler E (1999) New developments in hereditary hemochromatosis. Am J Med Sci 318:257–268CrossRefPubMed Felitti VJ, Beutler E (1999) New developments in hereditary hemochromatosis. Am J Med Sci 318:257–268CrossRefPubMed
4.
go back to reference Niederau C, Fisher R, Purschel A, Stremmel W, Haussinger D et al (1996) Long-term survival in patients with hereditary hemachromatosis. Gastroenterology 110:1107–1119PubMed Niederau C, Fisher R, Purschel A, Stremmel W, Haussinger D et al (1996) Long-term survival in patients with hereditary hemachromatosis. Gastroenterology 110:1107–1119PubMed
5.
go back to reference Hanson EH, Imperatore G, Burke W (2001) HFE gene and hereditary hemochromatosis: a HuGE review. Human genome epidemiology. Am J Epidemiol 154:193–206CrossRefPubMed Hanson EH, Imperatore G, Burke W (2001) HFE gene and hereditary hemochromatosis: a HuGE review. Human genome epidemiology. Am J Epidemiol 154:193–206CrossRefPubMed
6.
go back to reference Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA et al (1996) A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 13:399–408CrossRefPubMed Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA et al (1996) A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 13:399–408CrossRefPubMed
7.
go back to reference The UK Haemochromatosis Consortium (1997) A simple genetic test identifies 90% of UK patients with haemochromatosis. Gut 41:841–844 The UK Haemochromatosis Consortium (1997) A simple genetic test identifies 90% of UK patients with haemochromatosis. Gut 41:841–844
8.
go back to reference Camaschella C, Fargion S, Sampietro M, Roetto A, Bosio S et al (1999) Inherited HFE-unrelated hemochromatosis in Italian families. Hepatology 29:1563–1564CrossRefPubMed Camaschella C, Fargion S, Sampietro M, Roetto A, Bosio S et al (1999) Inherited HFE-unrelated hemochromatosis in Italian families. Hepatology 29:1563–1564CrossRefPubMed
9.
go back to reference Aguilar-Martinez P, Bismuth M, Picot MC, Thelcide C, Pageaux GP et al (2001) Variable phenotypic presentation of iron overload in H63D homozygotes: are genetic modifiers the cause? Gut 48:836–842CrossRefPubMed Aguilar-Martinez P, Bismuth M, Picot MC, Thelcide C, Pageaux GP et al (2001) Variable phenotypic presentation of iron overload in H63D homozygotes: are genetic modifiers the cause? Gut 48:836–842CrossRefPubMed
10.
go back to reference Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJH (1997) Global prevalence of putative haemochromatosis mutations. J Med Genet 34:275–278PubMed Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJH (1997) Global prevalence of putative haemochromatosis mutations. J Med Genet 34:275–278PubMed
12.
go back to reference Milman N, A Steig T, Koefoed P, Pedersen P, Fenger K, Nielsen FC (2005) Frequency of the hemochromatosis HFE mutations C282Y, H63D, and S65C in blood donors in the Faroe Islands. Ann Hematol 84:146–149CrossRefPubMed Milman N, A Steig T, Koefoed P, Pedersen P, Fenger K, Nielsen FC (2005) Frequency of the hemochromatosis HFE mutations C282Y, H63D, and S65C in blood donors in the Faroe Islands. Ann Hematol 84:146–149CrossRefPubMed
13.
go back to reference Milman N, Pedersen P, Ovesen L, Melsen GV, Fenger K (2004) Frequency of the C282Y and H63D mutations of the hemochromatosis gene (HFE) in 2501 ethnic Danes. Ann Hematol 83:654–657CrossRefPubMed Milman N, Pedersen P, Ovesen L, Melsen GV, Fenger K (2004) Frequency of the C282Y and H63D mutations of the hemochromatosis gene (HFE) in 2501 ethnic Danes. Ann Hematol 83:654–657CrossRefPubMed
14.
go back to reference Bauduer F, Scribans C, Degioanni A, Renoux M, Dutour O (2005) Distribution of the C282Y and H63D polymorphisms in hereditary hemochromatosis patients from the French Basque country. Ann Hematol 84:99–102CrossRefPubMed Bauduer F, Scribans C, Degioanni A, Renoux M, Dutour O (2005) Distribution of the C282Y and H63D polymorphisms in hereditary hemochromatosis patients from the French Basque country. Ann Hematol 84:99–102CrossRefPubMed
15.
go back to reference Simsek H, Sumer H, Yilmaz E, Balaban YH, Ozcebe O, Hascelik G, Buyukask Y, Tatar G (2004) Frequency of HFE mutations among Turkish blood donors according to transferrin saturation. J Clin Gastroenterol 38:671–675CrossRefPubMed Simsek H, Sumer H, Yilmaz E, Balaban YH, Ozcebe O, Hascelik G, Buyukask Y, Tatar G (2004) Frequency of HFE mutations among Turkish blood donors according to transferrin saturation. J Clin Gastroenterol 38:671–675CrossRefPubMed
16.
go back to reference El-Serag HB, Inadomi JM, Kowdley KV (2000) Screening for hereditary hemochromatosis in siblings and children of affected patients. A cost-effectiveness analysis. Ann Intern Med 132:261–269PubMed El-Serag HB, Inadomi JM, Kowdley KV (2000) Screening for hereditary hemochromatosis in siblings and children of affected patients. A cost-effectiveness analysis. Ann Intern Med 132:261–269PubMed
18.
go back to reference EASL (2000) International consensus conference on hemochromatosis. J Hepatol 33:485–504 EASL (2000) International consensus conference on hemochromatosis. J Hepatol 33:485–504
19.
go back to reference Krawczak M, Cooper DN, Schmidtke J (2001) Estimating the efficacy and efficiency of cascade genetic screening. Am J Hum Genet 69:361–370CrossRefPubMed Krawczak M, Cooper DN, Schmidtke J (2001) Estimating the efficacy and efficiency of cascade genetic screening. Am J Hum Genet 69:361–370CrossRefPubMed
20.
go back to reference Papanikolaou G, Politou M, Roetto A et al (2001) Linkage to chromosome 1q in Greek families with juvenile hemochromatosis. Blood Cells Mol Dis 27(4):744–749CrossRefPubMed Papanikolaou G, Politou M, Roetto A et al (2001) Linkage to chromosome 1q in Greek families with juvenile hemochromatosis. Blood Cells Mol Dis 27(4):744–749CrossRefPubMed
21.
go back to reference Wallace DF, Pedersen P, Dixon JL et al (2002) Novel mutation in ferroportin1 is associated with autosomal dominant hemochromatosis. Blood 100:692–694CrossRefPubMed Wallace DF, Pedersen P, Dixon JL et al (2002) Novel mutation in ferroportin1 is associated with autosomal dominant hemochromatosis. Blood 100:692–694CrossRefPubMed
22.
go back to reference Barosia G, Salvaneschi L, Grasso M et al (2002) High prevalence of screening-detected, HFE-unrelated, mild idiopathic iron overload in northern Italy. Haematologica 87(5):472–478PubMed Barosia G, Salvaneschi L, Grasso M et al (2002) High prevalence of screening-detected, HFE-unrelated, mild idiopathic iron overload in northern Italy. Haematologica 87(5):472–478PubMed
23.
go back to reference Montosi G, Donovan A, Totaro A et al (2001) Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. J Clin Invest 108(4):521–522CrossRefPubMed Montosi G, Donovan A, Totaro A et al (2001) Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. J Clin Invest 108(4):521–522CrossRefPubMed
24.
go back to reference Piperno A, Arosio C, Fossati L et al (2000) Two novel nonsense mutations of HFE gene in five unrelated Italian patients with hemochromatosis. Gastroenterology 119(2):441–445PubMed Piperno A, Arosio C, Fossati L et al (2000) Two novel nonsense mutations of HFE gene in five unrelated Italian patients with hemochromatosis. Gastroenterology 119(2):441–445PubMed
25.
go back to reference Pietrangelo A, Montosi G, Totaro A et al (1999) Hereditary hemochromatosis in adults without pathogenic mutations in the hemochromatosis gene. N Engl J Med 341(10):725–727CrossRefPubMed Pietrangelo A, Montosi G, Totaro A et al (1999) Hereditary hemochromatosis in adults without pathogenic mutations in the hemochromatosis gene. N Engl J Med 341(10):725–727CrossRefPubMed
26.
go back to reference Njajou OT, Vaessen N, Joosse M et al (2001) A mutation in SCL11A3 is associated with autosomal dominant hemochromatosis. Nat Genet 28:213–214CrossRefPubMed Njajou OT, Vaessen N, Joosse M et al (2001) A mutation in SCL11A3 is associated with autosomal dominant hemochromatosis. Nat Genet 28:213–214CrossRefPubMed
Metadata
Title
Mutations of the HFE gene among Turkish hereditary hemochromatosis patients
Authors
Halis Simsek
Yasemin H. Balaban
Engin Yilmaz
Hale Sumer
Yahya Buyukasik
Cem Cengiz
Osman Ozcebe
Gulsen Hascelik
Gonca Tatar
Publication date
01-10-2005
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 10/2005
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-005-1048-y

Other articles of this Issue 10/2005

Annals of Hematology 10/2005 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine